Insulet Takes 31% Target Hit, Akamai Soars

Barclays delivered one of the day's starkest analyst calls, slashing its price target on PODD from $286 to $198 — a 31% cut. The firm kept its Sell rating on the insulin pump maker. PODD carries an $11.1B market cap and short interest of 3.8% of free float. That target cut stands out as the most aggressive on today's tape.

On the other side, AKAM saw its consensus target jump sharply. It moved from $114 to nearly $139 — a 21% lift. The CDN and cloud security provider has short interest of nearly 12% of free float. That elevated short positioning could amplify any upside move if bulls gain traction.

Oilfield giant SLB also got a boost. Barclays analyst David Anderson raised his target from $51 to $66, a 29% increase, while maintaining a Buy. The call looks bold against a soft oil price backdrop.

Lithium producer ALB got a nudge higher from Truist Securities, with the target moving from $245 to $260. Barclays separately trimmed its target on WYNN from $143 to $139, reflecting continued caution on Macau-exposed gaming names.